YouTube video by MarcDarkTV

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases,

Surrozen (NASDAQ:SRZN), a biotechnology company focused on Wnt pathway therapeutics for eye diseases, reported Q2 2025 financial results and significant organizational developments. The company ended Q2 with $90.4 million in cash, down from $101.6 million in Q1, and posted net income of $39.7 million ($2.55 per share).Key developments include the appointment of Dr. Daniel Chao as VP of Clinical Development, formation of a Clinical Advisory Board with leading retinal specialists, and receipt of a U.S. patent for their SWAP™ technology. The company's lead candidates, SZN-8141 and SZN-8143, continue progressing, with an IND submission for SZN-8141 planned for 2026.Research revenue was $1.0 million, while R&D expenses increased to $6.0 million from $5.3 million year-over-year. The significant net income was primarily driven by non-cash gains from changes in fair value of tranche liability and warrant liabilities.

Latest patent strengthens Surrozen's position in targeted therapeutics with novel Wnt pathway technology. Discover how this impacts tissue repair innovation. See details.

Surrozen (NASDAQ: SRZN) reported Q1 2025 financial results and announced a strategic pivot to ophthalmology. The company has discontinued SZN-043 for alcohol-associated hepatitis due to insufficient clinical benefits and is now focusing on eye disease treatments. Their lead candidates SZN-8141 and SZN-8143 target AMD and diabetic retinopathy, with IND filing expected in 2026. The company secured a $175 million private placement, with $76.4 million received in March 2025. Q1 financial results showed cash position of $101.6 million, R&D expenses of $6.6 million, and a net loss of $27.0 million ($7.43 per share). FDA clearance of the IND would trigger $98.6 million in additional funding. The company maintains collaboration with Boehringer Ingelheim on SZN-413 for retinal vascular diseases.

Surrozen (NASDAQ:SRZN – Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, April 9th. Analysts expect Surrozen to post earnings of ($2.54) per share for the quarter. Surrozen (NASDAQ:SRZN – Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($9.10) EPS for […]

Strategic $175M financing bolsters Surrozen's ophthalmology pipeline as Boehringer advances SZN-413 program. See full financial results and milestone achievements.

Surrozen (NASDAQ: SRZN) announced a strategic shift to focus on ophthalmology programs, supported by an oversubscribed $175 million private placement. The funding will advance multiple eye disease treatments through Phase 1 studies.The company's two lead candidates for retinopathies are SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6), targeting conditions like AMD, diabetic retinopathy, and other severe eye diseases. Both compounds have shown promise in preclinical models by stimulating Wnt signaling and promoting normal retinal vessel growth while inhibiting pathological vessel development.Surrozen will discontinue the development of SZN-043 for severe alcohol-associated hepatitis, despite its safety profile, due to insufficient early clinical benefit signals. The private placement consists of two tranches: an initial $70 million closing around March 26, 2025, and a second $105 million tranche contingent on FDA clearance of the SZN-8141 IND, expected in 2026.